Ads
related to: monoclonal antibodyacrobiosystems.com has been visited by 10K+ users in the past month
Search results
Mirikizumab Shows Promise for Moderate to Severe Crohn's
Medscape· 18 hours agoAlready approved for ulcerative colitis, the monoclonal antibody mirikizumab met study endpoints for...
Duoning Collaborates with Bioelectronica to Commercialize a Single-Cell Sorting System for Antibody...
FOX 23 News Albany· 11 hours agoDuoning Biotechnology Group ("Duoning"), a leading one-stop bioprocess provider in China, today...
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
InvestorPlace· 6 hours agoFundamentally, one of the biggest advantages of biotech stocks to buy centers on the underlying...
Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 1 day agoNew indicators of a cooling economy eased inflation concerns, driving the S&P 500 to record highs...
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis -...
Benzinga· 5 days agoCelldex Therapeutics, Inc. CLDX today announced that the first patient has been dosed in the Company's Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is ...
Sanofi to make €1bn biomanufacturing investment in France
Pharmaceutical Technology via Yahoo Finance· 7 days agoSanofi plans to invest €1bn in Vitry-sur-Seine to construct a new unit in a bid to double the ...
Adagene Inc. (NASDAQ:ADAG) Short Interest Up 6.3% in April
ETF DAILY NEWS· 4 days agoAdagene Inc. (NASDAQ:ADAG – Get Free Report) saw a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 15,100 shares, an increase ...
5 Things to Know: COVID-19 Vaccines for Immunocompromised People
Medscape· 5 days agoCDC experts share what clinicians should know about COVID-19 prevention in immunocompromised...
Blackstone-backed biotech launches with up to $300M for immune drug
BioPharma Dive via Yahoo Finance· 5 days agoThe drug, solrikitug, originally came from Merck and has the potential to treat a variety of immune...
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
Benzinga· 5 hours agoNOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive
Ads
related to: monoclonal antibody
